AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 68 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $26,862 | -72.0% | 11,679 | -42.0% | 0.00% | – |
| Q4 2021 | $96,000 | -52.2% | 20,139 | -20.5% | 0.00% | – |
| Q3 2021 | $201,000 | +8.6% | 25,323 | -4.5% | 0.00% | – |
| Q2 2021 | $185,000 | -19.6% | 26,523 | -8.8% | 0.00% | – |
| Q1 2021 | $230,000 | +0.4% | 29,097 | -0.1% | 0.00% | – |
| Q4 2020 | $229,000 | +25.1% | 29,124 | +13.1% | 0.00% | – |
| Q3 2020 | $183,000 | -22.5% | 25,754 | 0.0% | 0.00% | – |
| Q2 2020 | $236,000 | +171.3% | 25,754 | +38.6% | 0.00% | – |
| Q1 2020 | $87,000 | -34.6% | 18,583 | +6.8% | 0.00% | – |
| Q4 2019 | $133,000 | -11.3% | 17,398 | -11.3% | 0.00% | – |
| Q3 2019 | $150,000 | +11.9% | 19,622 | +0.5% | 0.00% | – |
| Q2 2019 | $134,000 | -7.6% | 19,526 | +42.0% | 0.00% | – |
| Q2 2018 | $145,000 | – | 13,755 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |